LLY

1,027.44

+2.13%↑

JNJ

211.44

+0.72%↑

ABBV

223.45

-0.16%↓

UNH

341.39

+1.44%↑

AZN

89.79

-0.45%↓

LLY

1,027.44

+2.13%↑

JNJ

211.44

+0.72%↑

ABBV

223.45

-0.16%↓

UNH

341.39

+1.44%↑

AZN

89.79

-0.45%↓

LLY

1,027.44

+2.13%↑

JNJ

211.44

+0.72%↑

ABBV

223.45

-0.16%↓

UNH

341.39

+1.44%↑

AZN

89.79

-0.45%↓

LLY

1,027.44

+2.13%↑

JNJ

211.44

+0.72%↑

ABBV

223.45

-0.16%↓

UNH

341.39

+1.44%↑

AZN

89.79

-0.45%↓

LLY

1,027.44

+2.13%↑

JNJ

211.44

+0.72%↑

ABBV

223.45

-0.16%↓

UNH

341.39

+1.44%↑

AZN

89.79

-0.45%↓

Search

CareDx Inc

Gesloten

SectorGezondheidszorg

20.57 4.95

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

20.33

Max

20.62

Belangrijke statistieken

By Trading Economics

Inkomsten

10M

1.7M

Verkoop

13M

100M

K/W

Sectorgemiddelde

14.766

77.671

Winstmarge

1.674

Werknemers

644

EBITDA

11M

6.8M

Aanbevelingen

By TipRanks

Aanbevelingen

Buy

12 Maanden Prognose

+16.73% upside

Marktinformatie

By TradingEconomics

Marktkapitalisatie

220M

1B

Vorige openingsprijs

15.62

Vorige sluitingsprijs

20.57

Nieuwssentiment

By Acuity

40%

60%

107 / 374 Rangschikking in Healthcare

Technische score

By Trading Central

Vertrouwen

Neutral Evidence

CareDx Inc Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

13 dec 2025, 00:04 UTC

Acquisities, Fusies, Overnames

Intel in Talks to Acquire SambaNova in Deal Valued at $1.6 Billion, Bloomberg Reports, Citing Sources

12 dec 2025, 16:42 UTC

Acquisities, Fusies, Overnames

FTC Sues to Block Henkel's $725 Million Deal for Liquid Nails From PE Firm -- 2nd Update

13 dec 2025, 16:48 UTC

Acquisities, Fusies, Overnames

How the War to Win Warner Bros. Discovery Will Be Won -- Barrons.com

13 dec 2025, 08:00 UTC

Acquisities, Fusies, Overnames

How the War to Win Warner Bros. Discovery Will Be Won -- Barrons.com

13 dec 2025, 07:00 UTC

Acquisities, Fusies, Overnames

A Chubb/AIG Deal Could Be Good for Shareholders and a Coup for Greenberg Family -- Barrons.com

13 dec 2025, 00:24 UTC

Acquisities, Fusies, Overnames

Want a Piece Of SpaceX? -- Barrons.com

12 dec 2025, 23:49 UTC

Acquisities, Fusies, Overnames

Intel in Talks to Acquire SambaNova in Deal Valued at $1.6B, Bloomberg Reports, Citing Sources

12 dec 2025, 22:52 UTC

Marktinformatie

Nike Expected to Show Further Momentum in 2Q Results -- Market Talk

12 dec 2025, 22:32 UTC

Winsten

These Stocks Moved the Most Today: Broadcom, Oracle, Fermi, Tilray, Lululemon, Costco, Netskope, and More -- Barrons.com

12 dec 2025, 21:50 UTC

Marktinformatie

Basic Materials Roundup: Market Talk

12 dec 2025, 20:45 UTC

Winsten

The Best Dividend ETF for Right Now -- and 2026 -- Barrons.com

12 dec 2025, 20:41 UTC

Marktinformatie

Oil Ends Week Lower As Market Frets About Oversupply -- Market Talk

12 dec 2025, 20:20 UTC

Marktinformatie

U.S. Natural Gas Futures Post Hefty Weekly Loss -- Market Talk

12 dec 2025, 19:23 UTC

Winsten

Charles Schwab Is Opening New Accounts and Hauling in New Assets Amid Buoyant Stock Market -- Barrons.com

12 dec 2025, 18:35 UTC

Acquisities, Fusies, Overnames

PNC Financial Expects to Close FirstBank Deal On or About Jan. 5, Subject to Satisfaction of Customary Closing Conditions

12 dec 2025, 18:33 UTC

Acquisities, Fusies, Overnames

PNC Receives Regulatory Approvals For Acquisition Of FirstBank >PNC

12 dec 2025, 18:31 UTC

Marktinformatie

U.S. Oil Rig Count Edges Up by 1 to 414 -- Market Talk

12 dec 2025, 17:49 UTC

Winsten

Tariffs Mean Costco Has Fewer Product Types This Holiday. But It Has Plenty of Pies. -- WSJ

12 dec 2025, 17:34 UTC

Acquisities, Fusies, Overnames

Orange: Closing Subject to Customary Regulatory Approvals, Other Closing Conditions

12 dec 2025, 17:33 UTC

Acquisities, Fusies, Overnames

Orange: Closing of the Transaction Is Expected in the First Half of 2026

12 dec 2025, 17:33 UTC

Acquisities, Fusies, Overnames

Orange: Agreement Confirms the Non-Binding Agreement That Was Previously Announced Oct. 31

12 dec 2025, 17:32 UTC

Acquisities, Fusies, Overnames

Orange: MasOrange Is Spain's Leading Operator in Terms of Customer Base

12 dec 2025, 17:31 UTC

Acquisities, Fusies, Overnames

Orange to Buy the Stake for EU4.25B in Cash

12 dec 2025, 17:24 UTC

Marktinformatie

Argentina Predicts Record Wheat Crop -- Market Talk

12 dec 2025, 17:20 UTC

Marktinformatie
Winsten

Tech, Media & Telecom Roundup: Market Talk

12 dec 2025, 17:20 UTC

Marktinformatie

Basic Materials Roundup: Market Talk

12 dec 2025, 17:18 UTC

Marktinformatie
Winsten

Broadcom, Oracle Investor Reactions Show High Bar for AI Cos. -- Market Talk

12 dec 2025, 17:09 UTC

Marktinformatie

Broadcom Investors Were Primed to Sell Shares -- Market Talk

12 dec 2025, 17:09 UTC

Marktinformatie

Global Equities Roundup: Market Talk

12 dec 2025, 16:47 UTC

Marktinformatie

Broadcom's Margins Expected to Narrow Due to AI Revenue -- Market Talk

Peer Vergelijking

Prijswijziging

CareDx Inc Prognose

Koersdoel

By TipRanks

16.73% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 24 USD  16.73%

Hoogste 26 USD

Laagste 22 USD

Gebaseerd op 4 Wall Street-analisten die 12-maands prijsdoelen bieden voor CareDx Inc - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Buy

4 ratings

2

Buy

2

Hold

0

Sell

Technische score

By Trading Central

14.77 / 18.49Steun & Weerstand

Korte Termijn

Neutral Evidence

Gemiddeld Termijn

Strong Bearish Evidence

Lange Termijn

Weak Bearish Evidence

Sentiment

By Acuity

107 / 374 Rangschikking in Gezondheidszorg

Nieuwssentiment

Bullish Bewijs

Volatiliteit

Onder gemiddelde

Nieuws Volume (RCV)

Boven gemiddelde

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

$

Over CareDx Inc

CareDx, Inc. engages in the discovery, development, and commercialization of diagnostic solutions for transplant patients and caregivers in the United States and internationally. It also provides AlloSure Kidney, a donor-derived cell-free DNA (dd-cfDNA) solution for kidney transplant patients; AlloMap Heart, a gene expression solution for heart transplant patients; AlloSure Heart, a dd-cfDNA solution for heart transplant patients; and AlloSure Lung, a dd-cfDNA solution for lung transplant patients. The company offers Olerup SSP, which is used to type human leukocyte antigen (HLA) alleles based on sequence specific primer technology; QTYPE that enables precision in HLA typing; and Ottr, a transplant patient management software. In addition, it provides AlloSeq Tx, a high-resolution HLA typing solution; AlloSeq cfDNA, a surveillance solution to measure dd-cfDNA in blood; AlloSeq HCT, a solution for chimerism testing for stem cell transplant recipients; Allocell, a surveillance solution that monitors the level of engraftment and persistence of allogeneic cells for patients who have received cell therapy transplants; and XynQAPI cloud-based transplant quality management software, as well as AlloCare, a mobile app that offers a patient-centric resource for transplant recipients. The company offers its products directly to customers, as well as through third-party distributors and sub-distributors. It has a license agreement with Illumina, Inc. for the distribution, development, and commercialization of NGS products and technologies; and Cibiltech SAS to commercialize iBox, a software for the predictive analysis of post-transplantation kidney allograft loss. The company was formerly known as XDx, Inc. and changed its name to CareDx, Inc. in March 2014. The company was incorporated in 1998 and is headquartered in South San Francisco, California.
help-icon Live chat